Clinical and laboratory parameters in a cohort of CLL patient: a single centre experience

Abstract

Introduction: For patients diagnosed with CLL, it is necessary to clinically stage the disease by both the Rai and Binet systems. Although both staging systems are related to systemic spread, disease severity, and prognosis, concurrent genomic and molecular aberrations could alter the clinical course and outcome and could influence treatment strategy and clinical trial selection.

Objective: The objective of this study was to determine the association of various clinical and laboratory parameters in CLL patients.

Method: All the patients diagnosed as Chronic Lymphocytic Leukemia from January 2010 to July 2013 were included. Institutional review board approved the study. Informed consent was obtained. Clinical and laboratory findings were retrieved retrospectively from patients file. SPSS ver17 was used for statistical analysis.

Results: A total of 49 patients were enrolled including 35(71%) males and 14(28.5%) females. Mean age was 60 years. Out of 49, 36 patients were symptomatic including fever (19), weight loss (15), and sweating (02). Visceromegaly was seen in 19 patients (38.7%) (Hepatomegaly in 07 and splenomegaly in 12 patients) and 16 patient had lymphadenopathy. According to Rai staging, stage 0 was seen 25(51%) patients, stage I in 15(30.6%), stage II in 11(22.4%), stage III in 14(28.5%) and stage IV in 12(24.4%) patients. According to Binet staging 08(16.3%) patients, stage A, 04(8.1%) in stage B and 17(34.6%) noted. On bone marrow biopsy pattern of infiltration was Interstitial in (14), diffuse in (21), nodular in (07), interstitial to diffuse in (07) seen. Immunohistochemistry panel showed anti CD5, CD20, CD23, D79a in most all the cases. ZAP 70 positivity was seen in 17(34.6%) patients.

Conclusion: In our center most of the patients were in Rai/Binet 0/A stage. About 1/3 showed ZAP 70 positivity which indicates poor prognosis. All the CLL patient should not only be staged but also other genomic markers be applied to stratify the management accordingly.

Keywords: rai/binet staging; ZAP 70, visceromegaly, bone marrow biopsy, ECOG

Abbreviations: CLL, chronic lymphocytic leukemia; LDT, lymphocyte doubling time; ß2-MG, ß2-microglobulin; ATM, ataxia telangiectasia mutated; TLC, total leucocyte count; SEER, surveillance, epidemiology and end results

Introduction

Chronic lymphocytic leukemia (CLL) is the frequent type of leukemia in the elderly individuals with an incidence of 4.1 in 100,000 according to the western data.1,2 However, about a third of patients are below 60 years of age at diagnosis, and accounts for 30% of adult leukemia.3 It is characterized by clonal proliferation and accumulation of mature B-cells in bone marrow, lymph nodes and lymphoid organs.4 The clinical course of patients with chronic lymphocytic leukemia is heterogeneous in nature, with some patients experiencing an aggressive disease progression while others having an indolent course of disease that does not require any treatment except for monitoring of the patient.5 Patient’s gender and performance status according to ECOG may act as adjuncts to predict the course of disease on individual basis, however, usually these parameters are not useful enough to allow an accurate prognostic counselling for the patient.6,7

The Binet and Rai clinical staging systems provide a prediction about the prognosis based on anemia, lymphocytosis, thrombocytopenia and extension of the leukemic infiltration in CLL.8 Apart from the prognosis, this particular staging system also lends a hand in the decision of either proceeding with the treatment or just keeping the patient under observation. However these systems do not provide help in predicting that which patient are lying in the better prognosis group i.e. Stage A of Binet or Grade 0 or 1 of Rai may or may not enter into the bad prognosis group i.e. Stage B Or C of Binet or Grades 2 to 4 of Rai and develop progressive disease in the future.9

Below is given the standard clinical staging systems along with the median survival period (Table 1).10 Although these staging systems play an important role in deciding the best form of treatment for the patients; other parameters to have been studied in terms of prognostic markers. Few of them include patient characteristics for example gender, age and performance status as well as laboratory parameters showing the tumor burden and disease activity reflected by elevated lymphocyte count, pattern of bone marrow infiltration, lymphocyte doubling time (LDT) and high LDH levels.9 A study was done to find the prognostic value of serum markers such as ß2-microglobulin (ß2-MG), soluble CD23 or thymidine kinase in CLL.11 Genetic markers of
tumor cells such as genomic aberrations, genetic abnormalities such as p53 and Ataxia Telangiectasia Mutated (ATM) was also studied for prognostic importance. The mutation status of the variable segments of immunoglobulin heavy chain genes (V\(_{\mu}\)), or surrogate markers for these factors (CD38, ZAP-70, LPL, etc)\(^{11,14}\) was also studied.

### Table 1 Staging with risk stratification and their approximate years of survival

| Binet staging system | Rai staging system | Stratification of Risk | Median survival period (years) |
|----------------------|--------------------|------------------------|-------------------------------|
| A                    | 0                  | Low risk               | ~15                           |
| B                    | I or II            | Intermediate risk      | 05-Jul                        |
| C                    | III or IV          | High risk              | 03-Apr                        |

### Table 2 Binet Staging

| Risk Stratification | Stage | Anemia | Thrombocytopenia | Lymphoid regions (Lymphadenopathy/Spleno- or Hepatomegaly) |
|---------------------|-------|--------|------------------|----------------------------------------------------------|
| Low                 | A     | No     | No               | <2 Lymphoid regions involved                              |
| Intermediate        | B     | No     | No               | >2 Lymphoid regions involved                              |
| High                | C     | Yes    | Yes              | >2 Lymphoid regions involved                              |

### Statistical analysis

Analysis of the data was done on SPSS version 17.0.

### Results

A total of 49 patients were included in the study out of which 35(71%) males and 14(29%) were females. Median age at the time of diagnosis was 58 years in our study was (Range: 39-80yrs). Following table gives the demographic characteristics of the patients (Table 3):

At the time of diagnosis, according to Binet staging 04(8.1%) patients were categorized in Stage A, 04(8.1%) patients in stage B and 17(34.6%) patients in Stage C were noted. On bone marrow biopsy, pattern of infiltration placed 07(14.2%) patients with Nodular infiltration, 14(28.5%) patients with Interstitial, 07(14.2%) patients with Interstitial to diffuse and 21(42.8%) patients with diffuse pattern of infiltration. We also grouped the patients according to their staging with Interstitial to diffuse and 21(42.8%) patients with diffuse pattern of infiltration. The table below gives our results.

Immunohistochemistry panel showed CD45, CD5, CD20, CD23, CD79a, CyclinD1 to reach to a diagnosis of CLL. Clinicopathological parameters were retrieved retrospectively from patient’s records. Presence of any visceromegaly or/and lymphadenopathy was also noted. Furthermore presence of patient’s constitutional symptoms such as fever, weight loss and sweating were recorded. For staging of the disease at the time of diagnosis, only the Binet clinical staging was used in our study (Table 2).
Table 3 Demographic characteristics

| Demographic Characteristics | Frequency (%) |
|----------------------------|----------------|
| Median age (Males)          | 60 years       |
| Median age (Females)        | 54 years       |
| Lymphadenopathy             | 16(32.6)       |
| Splenomegaly                | 12(24.4)       |
| Hepatomegaly                | 07(14.2)       |
| Fever                       | 19(38.7)       |
| Weight loss                 | 15(30.6)       |
| Sweating                    | 02(04)         |

Table 4 Pattern of Infiltration and their staging

| Staging                        | Frequency (%) |
|--------------------------------|---------------|
| **Nodular (N=7)**              |               |
| Stage A                        | 05(10.2)      |
| Stage B                        | 01(2.0)       |
| Stage C                        | 01(2.0)       |
| **Interstitial (N=14)**        |               |
| Stage A                        | 10(20.4)      |
| Stage B                        | 02(4.1)       |
| Stage C                        | 02(4.1)       |
| **Interstitial to Diffuse (N=07)** |             |
| Stage A                        | 01(2.0)       |
| Stage B                        | 01(2.0)       |
| Stage C                        | 06(12.2)      |
| **Diffuse (N=21)**            |               |
| Stage A                        | 04(8.2)       |
| Stage B                        | 01(2.0)       |
| Stage C                        | 16(32.7)      |

Table 5 ZAP-70 and the respective staging

| Stage  | Frequency (%) |
|--------|---------------|
| Stage A| 07(41.2)      |
| Stage B| 01(5.9)       |
| Stage C| 09(52.9)      |

Table 6 Del 17p and their frequency

| Stage  | Frequency (%) |
|--------|---------------|
| Stage A| 01(10%)       |
| Stage B| 01            |
| Stage C| 02(20%)       |

Discussion

Rai et al.²² and Binet et al.²¹ are the two clinical staging systems that have been established as standards to estimate the prognosis of CLL in patients. The disease, however, in previous study shows a heterogeneous pattern in individual patients with similar staging.⁹ Several studies have been done to identify various other clinical and biological factors that may have prognostic importance in addition to the classic assessment. The Binet and Rai clinical staging systems base their prediction of prognosis in B-CLL on anemia, thrombocytopenia and extension of the leukemic infiltration.⁴ The other parameters to have been studied in terms of prognostic markers are patient performance status according to ECOG along with the laboratory parameters that show the tumor burden and disease activity reflected by elevated lymphocyte count, pattern of bone marrow infiltration, lymphocyte doubling time (LDT) and high LDH levels. β2-microglobulin (β2-MG) and soluble CD23 have also been studied as prognostic markers in CLL. Recently, emphasis have been placed on the presence of genetic markers of tumor cells such as p53 and ATM and their implications if present as they give a poorer outcome to the patients disease. The variable segments of immunoglobulin heavy chain genes (V_{H}) and their markers such as CD38, ZAP-70 was also studied. In this study we evaluate the correlation between some of the above mentioned prognostic factors in CLL patients with their Binet staging and thus the prognosis of these patients.

In United States, the Surveillance, Epidemiology and End Results (SEER) in 2013 showed 67years and 72years as median age at the time of diagnosis in men and women respectively. In our study, the median age at diagnosis is 60 years for men and 54 years for women.²⁴-²⁶ The western data showed a median age of approximately 70years at the time of diagnosis for entire group²⁷ while in our study 58 years was the median age for the entire group. Our study showed a male preponderance (M:F ratio, 3:3:1) in a study group of 49patients which was similar to the western data also showing a male preponderance (M:F ratio, 1:7:1) although the difference between the proportions of the two genders in the western data was considerably less. Our study however was shown to negate the results conducted in Niger which comprised of sixty patients and showed female preponderance (M:F ratio, 1:3).²⁸ Although CLL is a disease of the elderly and its incidence as well as the prevalence is directly proportional to increasing age, recent studies show a rise in the proportion of younger patients due to frequent blood testing.²⁹ This same study had 15% patients who were below the age of 40 years which our study also showed as we had 3(6%) patients below the age of 40 years.²⁸

An extensive study of 329 patients led to bone marrow histology being designated as the beneficial predictor of prognosis with the diffuse pattern of infiltration being an indicator of poor prognosis.³⁰ Our study also showed that the majority of the patients who were found out to have diffuse pattern of infiltration also were placed in the stage C at the time of diagnosis confirming the results of the related study that diffuse infiltration leads to poorer outcome and minimum survival. Studies also show that the presence of ZAP-70 leads to excessive tyrosine kinase activity and thus to increased phosphorylation. This increased activity keeps the leukemic cells in an “activated” state, giving the disease an aggressive pattern to follow as well as poorer outcome in patients.²⁰,³¹ Our study also showed that out of the 17 patients who were found to be ZAP-70 positive, 09 patients were placed in Stage C at the time of diagnosis leading to the conclusion that the presence of ZAP-70 gives patients a poorer survival rate. Further prospective studies are required to evaluate the importance of the genetic aberrations as markers of prognosis in CLL.
Conclusion

In our center most of the patients were in Binet stage C. About one-third of the total patients showed ZAP-70 positivity which indicates early progression to advance stage and need of immediate therapeutic intervention. All the CLL patients should not only be staged according to Rai/Binet Staging Systems; but also other genomic markers like Cytogenetic studies should be carried out to stratify the management accordingly.

Financial disclosure

No financial disclosure to be documented

Acknowledgements

None.

Conflict of Interest

The authors have declared that no conflict of interest existed.

References

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics. CA Cancer J Clin. 2007;57(1):43–66.
2. Surveillance Epidemiology and End Results Cancer Statistics review. Spain: National Cancer Institute; 2010.
3. Shanafelt TD. Predicting clinical outcome in CLL: how and why. Hematology Am Soc Hematol Educ Program. 2009;1:421–429.
4. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med. 1995;333(16):1052–1057.
5. Mozaleeb Z, Hananzadeh Nazar Abadi MH, et al. Chronic lymphocytic leukemia and prognostic factor. Asian Pac J Cancer Prev. 2012;13(7):3009–3013.
6. Neil E Kay, Tait D Shanafelt. Shanafelt, MD. Prognostic factors in chronic lymphocytic leukemia and prognosis. Chronic Lymphocytic Leukemia. 2006;12(3 Pt 1):726–734.
7. Nolz JC, Tschumper RC, Pittner BT, et al. ZAP-70 expression in normal pro/pre B cells, mature B cells, and B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2002;8(1):207–207.
8. Montserrat E. New Prognostic Markers in CLL. Hematology Am Soc Hematol Educ Program. 2006;2006:279–284.
9. Hallek M, Langenmayer I, Nerl C, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, non-smoldering chronic lymphocytic leukemia. Blood. 1999;93(5):1732–1737.
10. Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol J. 2002;3(1):7–9.
11. Montserrat E. New Prognostic Markers in CLL. Hematology Am Soc Hematol Educ Program. 2006;2006:279–284.
12. Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol J. 2002;3(1):7–9.
13. Oseier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100(4):1177–1184.